AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00744380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
Study NCT00744380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
Study NCT00036855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00036855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV
Study NCT00036855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT00036855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation
Study NCT01511692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg/day injected subcutaneously for 4 weeks
Study NCT01511692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo, injected subcutaneously for 4 weeks
Study NCT01511692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
Study NCT01511692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Dose individually adjusted, administered orally for 4 weeks
Study NCT01511692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glimepiride
Description: Dose individually adjusted, administered orally for 4 weeks
Study NCT02158000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group A
Description: one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
Study NCT02453139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 month supervised and home based aerobic exercise intervention
Study NCT02662283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
Study NCT02662283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reh-acteoside
Description: Oral take and reh-acteoside (0.4g bid) for 8 weeks
Study NCT02937090 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: Blood sample will be drawn from participants at study entry.
Study NCT02937090 — intervention group
Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected from participants at study entry.
Study NCT00908050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
Study NCT00036855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT00036855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00908050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo comparator
Study NCT01685060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
Study NCT01794663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-305
Description: Intravenous infusion for 1 hour at start of transplant procedure
Study NCT02802735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration
Study NCT02802735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration
Study NCT00854984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Life to the Full
Description: A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
Study NCT00928499 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interstim (SNS)
Description: Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
Study NCT02094196 — intervention group
Intervention type: OTHER
Intervention: Alcohol detoxification
Description: Detoxified alcohol- dependent patients in an inpatient setting
Study NCT03797157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: H2MF
Description: H2MF is a human milk-based breastmilk fortifier for preterm infants
Study NCT03797157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine milk-based fortifier
Description: Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
Study NCT02049294 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab (Xolair)
Study NCT02049294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT03701061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
Study NCT03701061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Influenza Vaccine
Description: A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
Study NCT02949414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
Description: The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
Study NCT01624974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 150 mg tablets taken QD
Study NCT01624974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets (matching the MK-1029 150 mg tablets) QD
Study NCT01624974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast (ML)
Description: ML 10 mg tablets QD
Study NCT03114670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
Description: a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
Study NCT00869375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular peripheral intervention
Description: Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
Study NCT02597686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SD-PB training
Study NCT04176328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.
Description: Teicoplanin Sandoz administered by inhalation (aerosol).
Study NCT02649075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived Bovine Immunoglobulin / Protein Isolate
Description: Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
Study NCT02649075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
Study NCT01841086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study NCT01841086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study NCT01841086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UI03SPG300CT
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study NCT01841086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI03SPG300CT
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study NCT03581565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zinc polycarboxylate (with the requirements of ISO 9917)
Description: intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
Study NCT02811081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Deflation
Description: In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
Study NCT02811081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline Instillation
Description: In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
Study NCT02811081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline Instillation + Pulmonary Recruitment
Description: In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
Study NCT02513355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
Study NCT02513355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changchun marina
Description: 25mg/m2,d1 and d8,q21d×4
Study NCT02513355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2,d1, q21d×4
Study NCT02513355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 135-175mg/m2,d1,q21d×4
Study NCT02513355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parapl
Description: AUC=5-6,d1,q21d×4
Study NCT03177473 — intervention group
Intervention type: DEVICE
Intervention: CervicalStim bone growth stimulator
Description: Orthofix CervicalStim bone growth stimulator
Study NCT01116128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 100 mg QD continuously (from day 1 to day 28)
Study NCT01116128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
Study NCT01116128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
Study NCT02385292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculeve Intranasal Lacrimal Neurostimulator
Description: The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
Study NCT02385292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal Lacrimal Neurostimulator
Description: The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
Study NCT03934515 — intervention group
Intervention type: OTHER
Intervention: etCO2
Description: At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values.
Study NCT03934515 — intervention group
Intervention type: OTHER
Intervention: pH
Description: At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values.
Study NCT03037333 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvenous cardiac pacing guided by fluoroscopy
Description: Transvenous cardiac estimulation
Study NCT03037333 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvenous cardiac pacing guided by ECG/ECHO
Description: Transvenous cardiac estimulation
Study NCT01320033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD2475/101 40 mg
Description: Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.
Study NCT01320033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 mg
Description: Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks
Study NCT01320033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Study NCT01320033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Study NCT01320033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Study NCT02045979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Description: BI 695501 single s.c. injection
Study NCT02045979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab-EU source
Description: adalimumab-EU source single s.c. injection
Study NCT02045979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab-US source
Description: adalimumab-US source single s.c. injection.
Study NCT01072656 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation for Thalamic Pain Syndrome
Description: Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
Study NCT01072656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation for Thalamic Pain Syndrome
Description: Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
Study NCT00519571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImplantLock device
Description: dental implant
Study NCT01951976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
Study NCT01951976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Classes
Description: Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
Study NCT03507270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FABP
Description: Assessment of changes in FABP concentrations
Study NCT03108742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSORB
Description: dermal stapler for skin closure
Study NCT03108742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic intradermal suture
Description: intradermal suture for skin closure
Study NCT01485185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin lower dose
Description: Repeat, oral dose
Study NCT01485185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Repeat, oral dose
Study NCT01485185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Dop)
Description: Placebo to donepezil, Repeat, oral dose
Study NCT01485185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Gaba)
Description: Placebo to gabapentin, Repeat, oral dose
Study NCT01485185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin higher dose
Description: Repeat, oral dose
Study NCT04312815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)
Study NCT04312815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM03
Description: SM03: 600 mg intravenous (IV)
Study NCT04312815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 600 mg intravenous (IV)
Study NCT04312815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Methotrexate: 7.5-20 mg/wk oral
Study NCT04312815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Methotrexate: 7.5-20 mg/wk oral
Study NCT00864539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified milk
Description: daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
Study NCT00864539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plain milk
Description: daily intake of 200 ml plain milk
Study NCT00864539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified orange juice
Description: daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
Study NCT00864539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plain orange juice
Description: daily intake of 250 ml plain orange juice
Study NCT01794663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion for 1 hour at start of transplant procedure
Study NCT01932372 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib (Xeljanz)
Description: 5 mg Tablet BID
Study NCT01932372 — intervention group
Intervention type: DRUG
Intervention: Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
Description: Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
Study NCT03661307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03661307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study NCT03661307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04382586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 320 mg (4 x 80 mg) capsules administered orally once daily
Study NCT01189487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampicillin sodium/sulbactam sodium
Description: ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
Study NCT04304040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.